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Human respiratory syncytial virus (hRSV) is the most important
viral agent of pediatric respiratory infections worldwide. The only
specific treatment available today is a humanized monoclonal
antibody (Palivizumab) directed against the F glycoprotein, ad-
ministered prophylactically to children at very high risk of severe
hRSV infections. Palivizumab, as most anti-F antibodies so far
described, recognizes an epitope that is shared by the two
conformations in which hRSV_F can fold, the metastable prefusion
form and the highly stable postfusion conformation. We now de-
scribe a unique class of antibodies specific for the prefusion form
of this protein that account for most of the neutralizing activity of
either a rabbit serum raised against a vaccinia virus recombinant
expressing hRSV_F or a human Ig preparation (Respigam), which
was used for prophylaxis before Palivizumab. These antibodies
therefore offer unique possibilities for immune intervention
against hRSV, and their production should be assessed in trials
of hRSV vaccines.
Human respiratory syncytial virus (hRSV) is the most im-portant viral cause of severe respiratory tract disease in the
pediatric population worldwide (1) and is also of considerable
importance in the elderly and immunocompromised adults (2).
There is no vaccine available against this virus. A trial conducted
with formalin-inactivated hRSV in the 1960s did not confer
protection and was associated with enhanced disease in infants
upon natural infection with the virus (3).
hRSV belongs to the Pneumovirus genus of the Paramyxoviridae
family. The viral genome consists of a single-stranded RNA
molecule of negative polarity that encodes 11 proteins (4). Two of
these proteins are the major surface glycoproteins of the virion,
namely: (i) the attachment protein (G) that mediates binding of
the virus to the cell surface and (ii) the fusion protein (F) that
promotes fusion of the virus and cell membranes during virus
entry and also the fusion of the membranes of infected cells with
surrounding cells to form syncytia.
Neutralizing antibodies play a major role in protection against
hRSV infections. F and G proteins are the only viral antigens
able to induce both neutralizing antibodies and relatively long-
lived protection in animal models (5, 6). Passive transfer of these
antibodies protects mice and cotton rats against a hRSV chal-
lenge (7, 8). In human, high titers of serum neutralizing anti-
bodies correlate with protection of adult volunteers against a
hRSV challenge (9), and lower risk of hRSV infection in chil-
dren (10) and the elderly (11). These observations prompted the
prophylactic use of an Ig preparation (Respigam) containing
high titers of neutralizing antibodies to prevent hRSV infections
in high risk infants (12). Respigam has been replaced by a hu-
manized monoclonal antibody (Palivizumab) directed against the
hRSV_F glycoprotein (13), which is the only available medicinal
product specific for hRSV.
hRSV_F is a type I glycoprotein that assembles as a homo-
trimer. Each monomer is synthesized as an inactive precursor
(F0) that needs to be cleaved at two polybasic sites (I and II) to
become fusion competent (14). Site II is equivalent to the single
cleavage site of other paramyxovirus F proteins, which precedes
a hydrophobic fusion peptide that is inserted into the target
membrane during fusion. It has been postulated that the para-
myxovirus F proteins remain in a metastable prefusion confor-
mation in the virus particle until the virus binds to the target
membrane. The F protein is then activated to initiate a series of
conformational changes so that fusion occurs “at the right time
and in the right place” (15). After fusion, F acquires a highly
stable postfusion conformation determined mainly by the for-
mation of a six-helix bundle (6HB), composed of sequences of
two heptad repeats (HRA and HRB) from each monomer (16).
The free energy released during the transition of the F protein
from the prefusion to the postfusion structure drives the process
of membrane fusion.
Palivizumab and most α-F monoclonal antibodies (MAbs)
described so far recognizes the postfusion conformation of
hRSV_F, represented in an anchorless form of the F protein,
referred to as FTM- (17). This artificial protein, engineered to
remove the transmembrane region and the cytoplasmic tail of F,
is secreted to the culture medium and it folds spontaneously into
the postfusion conformation. However, neutralizing MAbs that
recognize FTM- inhibit infectivity if preincubated with the virus
before being used to infect cells (18); i.e., before the F protein is
activated for fusion. It is likely therefore that most α-F MAbs
hitherto described recognize epitopes shared by both the pre-
and postfusion forms of hRSV_F.
We have published that human Ig (Ig) preparations contain
neutralizing α-F antibodies that could be purified by binding to
FTM- covalently linked to Sepharose beads (19). However, the
antibodies that did not bind to FTM- retained most of the neu-
tralizing activity present in the Ig preparations (even after de-
pletion of α-G antibodies) and were able to bind to cells infected
with either hRSV or a recombinant vaccinia virus that expressed
hRSV_F. It appears therefore that certain human neutralizing
antibodies recognize structures of the F protein, other than those
represented in FTM-. We now report that this type of antibodies
can be obtained from rabbits immunized with recombinant vac-
cinia viruses expressing a full-length hRSV_F. In addition, both
rabbit and human neutralizing α-F antibodies, depleted of those
reacting with FTM-, bind to a prefusion form of hRSV_F,
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stabilized with intermonomeric disulfide bonds. These results
therefore offer possibilities to develop unique α-hRSV neutral-
izing antibodies with potential applications in the clinic.
Results
Induction of Neutralizing Antibodies in Rabbits Inoculated with Re-
combinant Vaccinia Viruses Expressing Either hRSV_F or hRSV_FTM-.
New Zealand White rabbits were inoculated intramuscularly
(i.m.) with recombinant vaccinia viruses expressing either a full-
length copy of hRSV_F (Vac/Fc) or an anchorless mutant of the
same protein (Vac/FTM-). Representative results of each group of
rabbits, shown in Fig. 1, demonstrated that both sera contained
antibodies able to bind to purified FTM- in an ELISA (Fig. 1A)
and to inhibit hRSV infectivity in a microneutralization test (Fig.
1B). However, the sera of rabbits inoculated with Vac/Fc (named
α-Fc, see Methods for the system used to label the antibodies)
neutralized hRSV significantly better than the sera of rabbits
inoculated with Vac/FTM- (α-FTM-).
The α-Fc antibodies were purified with protein A-Sepharose
and subsequently loaded onto a column of FTM- protein co-
valently linked to Sepharose beads. As expected, the antibodies
that did not bind to the column (α-Fc/ΔFTM-) failed to react with
the FTM- protein in an ELISA (Fig. 1C), whereas the α-Fc/FTM-
antibodies eluted from the column showed a higher level of
binding to FTM- than the starting antibodies (α-Fc). Remarkably,
although the α-Fc/FTM- antibodies inhibited hRSV infectivity
in a neutralization test, the unbound α-Fc/ΔFTM- antibodies re-
tained most of the neutralizing activity of the original α-Fc
antibodies (Fig. 1D). Considering that the antibodies eluted from
the affinity column (α-Fc/FTM-) should be specific only for the F
protein whereas α-Fc and α-Fc/ΔFTM- antibodies should contain
multiple specificities present in a rabbit serum, the results of Fig.
1D underscore the neutralizing capacity of α-Fc/ΔFTM-, although
direct comparison of specific activities between α-Fc/FTM- and
α-Fc/ΔFTM- would require estimation of the percentage of F-
specific antibodies in each antibody preparation.
The antibodies from rabbits inoculated with Vac/FTM- (re-
ferred to as α-FTM-) were processed similarly to the α-Fc anti-
bodies. Again, the antibodies not retained in the column of FTM-
(α-FTM-/ΔFTM-) were unable to bind to this protein in an ELISA,
whereas the antibodies eluted from the column (α-FTM-/FTM-)
showed a higher level of binding to FTM- than the starting ma-
terial (Fig. 1E). However, in this case, the antibodies unbound to
the column of FTM- were unable to neutralize hRSV infectivity
(Fig. 1F), in clear distinction with the equivalent antibodies
obtained from rabbits inoculated with Vac/Fc (compare Fig. 1 D
and F). In addition, both α-FTM- and α-FTM-/FTM- antibodies
were significantly less neutralizing than the corresponding anti-
bodies obtained from rabbits inoculated with Vac/Fc (compare
the x axis of Fig. 1 D and F).
Characterization of the Neutralizing Activity of the α-Fc/ΔFTM-
Antibodies. Several tests were performed to confirm that the neu-
tralizing activity of the α-Fc/ΔFTM- antibodies was due to anti-
bodies specific against hRSV_F and not to spurious cross-reactions.
First, the reactivity of α-Fc, α-Fc/ΔFTM-, and α-Fc/FTM- anti-
bodies was tested by flow cytometry with HEp-2 cells infected
with hRSV. As shown in Fig. 2A, the α-Fc/ΔFTM- antibodies
could bind specifically to the surface of hRSV-infected cells,
although the level of fluorescence was lower than that achieved
with α-Fc and α-Fc/FTM-.
To exclude illegitimate cross-reactions of α-vaccinia virus
antibodies, the α-Fc, α-Fc/ΔFTM-, and α-Fc/FTM- preparations
were adsorbed to HEp-2 cells infected with a vaccinia recombi-
nant expressing the phosphoprotein (P) of hRSV (Vac/P). Before
adsorption, the three antibody preparations reacted positively by
flow cytometry with cells infected with either Vac/Fc or Vac/P
(Fig. 2B). However, after adsorption to HEp-2, cells infected with
Vac/P the reactivity with cells infected with this virus was lost
while the reactivity with cells infected with Vac/Fc remained es-
sentially unchanged (Fig. 2C). Finally, the three antibody prepa-
rations were adsorbed to HEp-2 cells infected with Vac/Fc. In this
case, the three adsorbed antibodies lost the reactivity with cells
infected with either Vac/P or Vac/Fc (Fig. 2D).
Antibody preparations were further analyzed for binding to
FTM- and hRSV neutralization before and after the adsorptions
of the previous paragraph. Adsorption to cells infected with Vac/
P (ΔVac) had no impact on either antibody binding to purified
FTM- (Fig. 3 A–C) or hRSV neutralization (Fig. 3 D–F). In
contrast, adsorption of the three antibody preparations to cells
infected with Vac/Fc reduced the reactivity of α-Fc (Fig. 3A)
and α-Fc/FTM- (Fig. 3C) to background levels, whereas the re-
activity of α-Fc/ΔFTM- remained negligible (Fig. 3B). The most
significant result was that the neutralizing activity of the three
antibody preparations was abrogated after adsorption to cells
infected with Vac/Fc (Fig. 3 D–F).
In summary, the neutralizing activity of α-Fc antibodies de-
pleted of those binding to FTM- (α-Fc/ΔFTM-) was removed by
adsorption to cells infected with Vac/Fc (Fig. 3E). At this point,
Fig. 1. Induction of binding and neutralizing antibodies in rabbits immu-
nized with recombinant vaccinia viruses expressing different forms of
hRSV_F. Serial dilutions of sera from rabbits inoculated with either Vac/Fc
(α-Fc) or Vac/FTM- (α-FTM-) were tested for binding to purified FTM- adsorbed
to ELISA plates (A) or hRSV neutralization (B). Control serum from a pre-
immune rabbit was included as control. Total α-Fc antibodies were purified
by protein A-Sepharose chromatography from the sera of rabbits immu-
nized with Vac/Fc. The α-Fc antibodies were loaded onto a column of FTM-
Sepharose, and the unbound antibodies (α-Fc/ΔFTM-) were collected and
saved. After washing, the antibodies bound to the column (α-Fc/FTM-) were
eluted. The α-Fc, α-Fc/ΔFTM-, and α-Fc/FTM- antibodies were then tested for
binding to FTM- (C) and for hRSV neutralization (D). Total α-FTM- antibodies
from rabbits inoculated with Vac/FTM- were processed similarly to yield the
α-FTM-/ΔFTM- antibodies that did not bind to the FTM-Sepharose column and
the α-FTM-/FTM- antibodies eluted from this column. α-FTM-, α-FTM-/ΔFTM-, and
α-FTM-/FTM- antibodies were tested for binding to FTM- (E) and hRSV neu-
tralization (F). Results are presented as means ± SEM of three independent
experiments.
3090 | www.pnas.org/cgi/doi/10.1073/pnas.1115941109 Magro et al.
we postulated that the α-Fc/ΔFTM- antibodies recognize a con-
formation of hRSV_F, which the protein adopts when inserted
into membranes but not when expressed as a soluble anchorless
molecule. The possibility that this conformation may correspond
to the prefusion formof hRSV_F is supported by the results of Fig.
S1. Thus, when hRSV was preincubated with saturating amounts
of α-Fc, α-Fc/ΔFTM-, or α-Fc/FTM- and then pelleted to eliminate
any free remaining antibodies before being used to infect new
cells, virus infectivity was already inhibited. Therefore, the three
antibody preparations (and, in particular, α-Fc/ΔFTM-) could bind
and neutralize hRSVbefore the F protein was activated for fusion.
The results of Fig. S1 also suggest that neutralizing α-Fc/FTM-
antibodies may recognize epitopes shared by the pre- and post-
fusion forms of hRSV_F (see below under Discussion).
Stabilization of the Prefusion Form of hRSV_F and Reactivity with
Rabbit and Human Antibodies. To test whether α-Fc/ΔFTM- anti-
bodies could bind to the prefusion form of hRSV_F removed
from a membrane environment, we attempted to purify this
protein in the prefusion conformation. Previous efforts to solu-
bilize the prefusion form of hRSV_F have failed, most likely
because of the metastable state of this conformation and its
spontaneous refolding to the postfusion form upon manipula-
tion. Therefore, stabilization of the prefusion form of hRSV_F
was attempted via the introduction of intermonomeric disulfide
bridges that would prevent refolding after solubilization (Fig.
4A). Several artificial disulfide bonds were designed, based on
a model of the prefusion hRSV_F (Fig. 4B), built with the atomic
coordinates of the structure solved for the homologous para-
influenza virus 5 (PIV5) F protein (20).The best results were
obtained with a protein referred to as FcN2C-C, in which four
amino acids were mutated to cysteines (shown schematically
in Fig. 4 A and B). The basic residues at the two polybasic
cleavage sites of FcN2C-C and the wild-type hRSV_F (referred as
FcN) were replaced by asparagine residues to avoid cleavage, as
done with PIV5 (20). Finally, a His-tag was added to the C
terminus of each protein to facilitate purification in Ni(2+)
columns, and both constructs were incorporated into vaccinia
virus recombinants. The location of introduced cysteine residues
is shown in homology models of both the pre- and postfusion
structures in Fig. 4 B and C. It is worth stressing that the extra
disulfide bonds can only be formed intermonomerically and only
if the F protein is in the prefusion conformation (Fig. 4B), but
not if refolded to the postfusion structure (Fig. 4C).
SDS/PAGE of boiled samples under nonreducing conditions
showed the presence after Coomassie blue staining of a high
molecular band (>250 kDa) in purified FcN2C-C—compatible
with a F protein trimer—which was absent in FcN (Fig. 4D).
Under these conditions, the FcN lane contained a major band
of ≈80 kDa, corresponding to the F monomer (F0) and a minor
band of ≈190 kDa, which might be an F protein dimer, although
Fig. 2. Rabbit α-Fc antibodies recognize HRSV_F expressed at the cell sur-
face even if depleted of antibodies able to bind to FTM- (α-Fc/ΔFTM-). HEp2
cells were infected with hRSV (Long strain, multiplicity of infection 5 pfu per
cell) and tested 48 h later by flow cytometry for cell surface labeling with
α-Fc, α-Fc/ΔFTM-, and α-Fc/FTM- antibodies (A). Alternatively, HEp-2 cells were
infected with recombinant vaccinia virus, either hRSV_P (Vac/P) or hRSV_Fc
(Vac/Fc), and tested 24 h later by flow cytometry for cell surface labeling
with α-Fc, α-Fc/FTM-, and α-Fc/ΔFTM- antibodies before (B) or after adsorption
of the antibodies to cells infected with Vac/P (C) or Vac/Fc (D). Mock infected
cells (dashed lines) were included always as control. Note the reactivity of
α-Fc/FTM- antibodies with cells infected with Vac/P (B Right), although lower
than the reactivity of α-Fc and α-Fc/ΔFTM- probably because anti-vaccinia
antibodies that bound unspecifically to the FTM- column. Results are repre-
sentative of at least three independent experiments.
Fig. 3. α-Fc, α-Fc/ΔFTM-, and α-Fc/FTM- antibodies lost their neutralizing
activity after incubation with cells infected with Vac/Fc. The three antibody
preparations of Fig. 2 were depleted of antibodies binding to cells infected
with either Vac/P (ΔVac) or Vac/Fc (ΔFc) and then tested either before or
after the different adsorptions for binding to FTM- (A–C) and for hRSV
neutralization (D–F). Although the antibodies incubated with cells infected
with Vac/Fc were also depleted of anti-vaccinia antibodies (i.e., they were
also ΔVac), they were labeled ΔFc to distinguish them of those incubated
with cells infected with Vac/P (labeled ΔVac in this figure). Results are pre-
sented as means ± SEM of three independent experiments.









the nature of this band has not been investigated further. These
two bands were seen as minor components of the unreduced
FcN2C-C, indicating that formation of the extra disulfide bonds
was not 100% efficient. Purified FTM- (also modified to change
the cleavage sites as in FcN and FcN2C-C; SI Methods) yielded
a single band migrating slightly faster than F0, in agreement with
its lower molecular mass. The relatedness of all these bands with
hRSV_F was demonstrated by Western blotting with α-FTM-
antibodies (Fig. 4E).
Electron microscopy of negatively stained FcN revealed cone-
shaped molecules with a uniform contour and size (Fig. 4G) that
resembled the structure of FTM- in the postfusion conformation
(Fig. 4F), except for a smaller globular density at one end of FcN
that may represent detergent bound to the transmembrane region
of this molecule and that is absent in FTM-. In contrast, FcN2C-C
molecules were morphologically more heterogeneous but with
a significant proportion of rounded shape structures (Fig. 4H),
resembling the heterogeneity and shape reported for the pre-
fusion form of PIV5_F (21). Recently, Chaiwatpongsakorn et al.
(22) have published electron micrographs of hRSV_F in the pre-
fusion conformation (obtained by alternative methods to those
used here) that also resemble the images of FcN2C-C molecules
shown in Fig. 4H.
The preparations of rabbit antibodies described in previous
sections were tested by ELISA for binding to purified FTM-, FcN,
and FcN2C-C proteins. The results of Fig. 5A demonstrate that
α-Fc and α-FTM- antibodies were able to bind similarly to the
three proteins, whereas α-Fc/ΔFTM- antibodies were able to bind
to FcN2C-C but failed to bind to FTM- and FcN. These results
strongly support the conclusion that α-Fc/ΔFTM- antibodies are
specific for the prefusion form of hRSV_F, represented in the
FcN2C-C and, therefore, do not require a membrane environment
for binding. The conclusion that the FcN2C-C protein is in the
prefusion conformation is further supported by the lack of
binding of antibodies specific for the 6-helix bundle (a structure
unique of the postfusion form), whereas these antibodies bound
efficiently to the FTM- and FcN proteins (Fig. 5A, Bottom Right).
We have reported that antibodies present in a human Ig
preparation (Respigam, RG) were capable of neutralizing hRSV
infectivity, even if depleted of those binding to FTM-(19). To
clarify the specificities of these antibodies, they were tested in a
sandwich ELISA with the FTM-, FcN, and FcN2C-C proteins. As
shown in Fig. 5A, Bottom Left, RG antibodies bound to the three
proteins; however, after depletion of the antibodies binding to
FTM-Sepharose (RG/ΔFTM-; Fig. 5A, Bottom Right), they failed
to bind to FTM- and FcN although continued to react with
FcN2C-C, mimicking the reactivity of rabbit α-Fc/ΔFTM- anti-
bodies. Furthermore, as reported (19), RG and RG/ΔFTM-
antibodies neutralized efficiently hRSV even if the later anti-
bodies were depleted of α-G antibodies (RG/ΔFTM-/ΔG) but not
if depleted additionally of antibodies that bound to cells infected
with Vac/Fc (RG/ΔFTM-/ΔG/ΔFc) or Vac/FcN2C-C (RG/ΔFTM-/
ΔG/ΔFcN2C-C) (Fig. 5B). Thus, a large proportion of the RG
neutralizing activity, raised presumably after natural infections
with hRSV, is afforded by antibodies able to bind specifically to
the prefusion form of hRSV_F and present at the surface of cells
infected with either Vac/Fc or Vac/FcN2C-C.
Remarkably, despite significant structural differences between
FcN2C-C and FcN (i.e., pre- and postfusion forms of hRSV_F;
Fig. 4 B and C), both proteins (and FTM-) bound similarly four
α-F MAbs specific to different epitopes, including palivizumab
used in the clinic (Fig. 5C).
Discussion
Most α-hRSV_F antibodies described so far in the literature
recognize epitopes present in the postfusion form of the F pro-
tein. Commonly, reactivity with purified FTM- or Fc or immuno-
precipitation of hRSV-infected cell extracts have been used to
assign antibody specificities. It is expected that under all of those
conditions the F protein will be folded in the postfusion confor-
mation, such as for the FcN protein of Fig. 4. Even virus prepa-
rations may contain a sizeable amount of F in the postfusion form,
as shown for PIV5_F (23). It is also known that preparations of
purified hRSV contain a large proportion of noninfectious par-
ticles in which the F protein could be in the postfusion form.
Fig. 4. Stabilization of the prefusion form of hRSV_F
with intermonomeric disulfide bonds. (A) Scheme of the
hRSV_F primary structure, denoting the three main hy-
drophobic regions: signal peptide (SP), fusion peptide
(FP), and transmembrane region (TM). Also indicated
are the two furin cleavage sites (arrows) that generate
the F2 and F1 chains and the cysteines (gray dots and
numbers) that participate in the intramonomeric disul-
fide bonds observed in the pos-fusion structure of hRSV.
HRA and HRB represent the heptad repeat sequences
of the F1 chain. Partial sequences, shown below the
scheme, highlight the asparagines (N, boldface) in-
troduced to ablate furin cleavage in FcN and FcN2C-C
constructs and the cysteines introduced in the latter
construct (shown in orange) to make new intermono-
meric disulfide bonds. The His-tag sequence added at
the C terminus is shown above the scheme. (B) 3Dmodel
of the prefusion conformation of hRSV_F built with the
coordinates of the PIV5_F protein (20) (PDB ID code
2B9B). Each monomer is colored differently. Cysteine
residues (C) replacing residues 481, 489, 509, and 510 in
FcN2C-C are represented by golden balls alternating in
two of themonomers (magenta and blue). (C) Postfusion
structure of hRSV_F, reported by MacLellan et al. (26)
(PDB ID code 3RRR). Colors and locations of engineered
cysteine residues are presented as in B. Purified FcN,
FcN2C-C, and FTM- proteins (Methods) were resolved by
SDS/PAGE and either stained with Coomassie blue (D) or
electrotransferred to nylon membranes and stained by
Western blot with α-FTM- antibodies (E). Electron mi-
croscopy of the three purified proteins (F–H) negatively
stained with uranyl acetate. (Scale bar: 50 nm.) Two-
times-magnified selected molecules are shown in Insets.
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Therefore, it was only after depletion of antibodies that bound to
FTM- that those specific for the prefusion form of hRSV_F could
be uncovered. These antibodies account for most of the neu-
tralizing activity found in human Ig preparations (not only
Respigam but also another Ig preparation, Flebogamma; ref. 24)
and in sera of rabbits inoculated with Vac/Fc. These antibodies,
however, were absent from sera of rabbits inoculated with Vac/
FTM-, illustrating the importance of the F protein structure pre-
sented to the immune system for the antibody outcome.
Previously we have shown that antibody affinity is crucial for
protection of mice from hRSV infection (25). It is likely that
a major proportion of the F protein present in the formalin or
UV inactivated virus or the purified F protein that failed to in-
duce protection in those studies was in the postfusion structure.
Taking into consideration our new results showing that anti-
bodies specific for the prefusion form of hRSV_F account for
most of the neutralizing activity of an immune response, it is
possible that absence of this form may have contributed to a
failure to produce a protective immune response.
The structure of hRSV_F in the postfusion conformation has
been solved recently by X-ray crystallography (26, 27). Modeling
of the prefusion form and comparison with the actual structure of
the postfusion form confirmed the preservation of local structures
in both conformations that contained epitopes recognized by
certain MAbs. These results are in full agreement with previous
electron microscopy studies of immune complexes of FTM- with
MAbs (17) and with the results of Fig. 5C, which showed cross-
reactivity of four MAbs with the pre- and postfusion forms of
hRSV_F. These results also explain the frequent isolation of
MAbs that recognize both conformations and the capacity of
MAbs or antibodies such as α-Fc/FTM- (Fig. S1) to inhibit virus
infectivity even before activation of the F protein for fusion (18).
At least a proportion of FcN and FcN2C-C proteins should
be in the prefusion form when expressed at the cell surface as
inferred from their capacity to deplete the α-Fc/ΔFTM- and RG/
ΔFTM- antibodies of their respective neutralizing activities (Fig.
S2 and Fig. 5B). However, it is worth pointing out that both
proteins were engineered to ablate the two cleavage sites re-
quired for activity and, consequently, remain uncleaved. There-
fore, subtle structural differences between those two proteins
(while inserted in the cell membrane) and the actual prefusion
protein may have escaped the antigenicity tests and electron
microscopy studies, carried out in the present work. When sol-
ubilized, however, FcN apparently refolded into the postfusion
form as seen by electron microscopy. In contrast, FcN2C-C (for
which the yield is 10–20 times lower than for FcN) was in-
homogeneous but contained a proportion of rounded molecules
that resemble the reported prefusion shapes of PIV-5 (21) and
Fig. 5. The stabilized prefusion hRSV_F protein is bound by rabbit and human neutralizing antibodies depleted of those that recognize FTM-. (A) The three
proteins, FTM-, FcN, and FcN2C-C of Fig. 4 were bound to ELISA plates via a bridge made with MAb 101F and then tested for binding to the antibodies indicated
at the bottom of each image. α-Fc, α-FTM-, and α-Fc/ΔFTM- have been described in Fig. 1. The α-6HB antibodies (Methods) were raised in rabbits inoculated with
a bacterially expressed construct that mimics the six-helix bundle present in the postfusion form of hRSV_F (28). RG is the Ig preparation (Respigam) used some
years ago in the clinic (a generous gift of MedImmune). A sample of this preparation was also depleted of antibodies binding to FTM-Sepharose (RG/ΔFTM-). (B)
RG was depleted sequentially of antibodies binding to FTM-Sepharose (RG/ΔFTM-), G-Sepharose (RG/ΔFTM-/ΔG), and cells infected with either Vac/Fc (RG/ΔFTM-/
ΔG/ΔFc) or Vac/FcN2C-C (RG/ΔFTM-/ΔG/ΔFcN2C-C), and all these antibody preparations were used in a microneutralization test with hRSV. C- is a preimmune
rabbit antibody. (C) FTM-, FcN, and FcN2C-C proteins were adsorbed directly to microtiter plates and used in an ELISA with the four MAbs indicated in each
image. 2F, 47F, and 101F are murine MAbs that recognize nonoverlapping epitopes in hRSV_F (29) Palivizumab (a generous gift of Abbott España) is a hu-
manized MAb in use as a prophylactic treatment for hRSV infections. Escape mutants selected with Palivizumab partially overlap those selected with MAb 47F
(30), and both antibodies bind to similar peptides of hRSV_F (31, 32).









hRSV_F proteins (22). FcN2C-C preparations also contain a
small proportion of molecules in which the additional cysteine
residues were not disulfide bonded, as seen by SDS/PAGE (Fig. 4
D and E). This heterogeneity was reproducibly found in several
preparations of FcN2C-C and was maintained at similar levels
during storage. Thus, additional efforts are needed to obtain ho-
mogeneous preparations of prefusion hRSV_F amenable for
structural studies. Furthermore, FcN2C-C (or other alternative
constructs) may require further improvements for efficient immu-
nogenicity, because preliminary results indicate that Vac/FcN2C-C
is able to induceneutralizing antibodies in rabbits but at lower titers
than Fc, most likely due to the lower expression level (Fig. S3).
The actual mechanism of neutralization by the antibodies
specific for the prefusion form of hRSV_F remains to be eluci-
dated. For instance, it is unknown whether the high neutralizing
capacity of the α-Fc/ΔFTM- or RG/ΔFTM- relies on synergistic
effects of antibodies binding simultaneously to several epitopes.
In this sense, it would be important to evaluate the neutralizing
potency of individual antibodies (e.g., MAbs) specific for the
prefusion form of hRSV_F in comparison with antibodies that
recognize epitopes shared by the prefusion and postfusion con-
formations, such as those of Fig. 5C. The availability of stabilized
prefusion forms of hRSV_F should facilitate the search of MAbs
or other type of molecules that bind specifically to this confor-
mation and interfere with its activation. This approach could be
used to develop a new generation of more effective prophylactic
antibodies for treatment of infants at high risk of hRSV infec-
tions or even extended to other paramyxoviruses for devel-
opment of novel prophylactic and/or therapeutic agents.
Methods
Preparation and Testing of Polyclonal Antibodies Directed Against Different
Forms of hRSV_F.New ZealandWhite rabbits were inoculated intramuscularly
(i.m.) with the vaccinia virus recombinants indicated in Fig. 1 legend on days
0 and 21 and bled 3 wk later. Serum antibodies were purified by using a
protein A-Sepharose column and further processed by affinity chromatog-
raphy to FTM- protein covalently linked to Sepharose beads. The unretained
fraction (named ΔFTM-; see SI Methods for antibody nomenclature) was
saved, and the bound antibodies were eluted with acidic buffer. The dif-
ferent antibody preparations were tested for ELISA binding to FTM- and virus
neutralization. Depletion of certain specific antibodies was also achieved
after incubation with cells infected with either hRSV or vaccinia virus
recombinants expressing different forms of the F protein. Human antibodies
present in Respigam were processed similarly to rabbit antibodies.
Stabilization of the Prefusion Form of hRSV_F. Vaccinia virus recombinant
expressing full-length F (Vac/Fc) has been described (17). This recombinant
was modified by changing the basic residues at the two cleavage sites of
hRSV_F to Asparagines as indicated in Fig. 4A to generate Vac/FcN. Addi-
tionally, the residues Leu481, Asp489, Ser509, and Asp510 of hRSV_F were
substituted by Cysteines to generate Vac/FcN2C-C. Finally, a His tag was added
to the C terminus of FcN and FcN2C-C for purification purposes. Additional
experimental details are provided in SI Methods.
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SI Methods
Viruses. The Long strain of hRSV was grown in HEp-2 cells with
DMEM supplemented with 2.5% FCS (DMEM2.5). Previously
synthesized recombinant vaccinia viruses expressing either the
phosphoprotein (Vac/P) (1), the G glycoprotein (Vac/G) (2), or
the full-length (Vac/Fc) or soluble forms (Vac/FTM-) of the
hRSV_F protein (3) were grown in CV-1 monkey as described.
Additional recombinant vaccinia viruses were made by the
method of Blasco and Moss (4), expressing either an uncleaved
version of hRSV_F with the basic amino acids at the two
cleavage sites Arg106, Arg108, Arg109, Lys131, Lys132, Arg133,
Lys134, Arg135, and Arg136 substituted with asparagines resi-
dues (Vac/FcN) or additionally having amino acids Leu481,
Asp489, Ser509, and Asp510 substituted with cysteine residues
(Vac/FcN2C-C) (Fig. 4A). Both FcN and FcN2C-C were addi-
tionally modified by the insertion of a 6His tag (Gly-Gly-Ile-Glu-
Gly-Arg-His-His-His-His-His-His) at the C terminus to facilitate
purification in Ni(2+) columns.
Protein Expression and Purification. A soluble, anchorless form of
the hRSV_F protein was purified from the supernatants of HEp-2
cells infected with Vac/FTM-, as described (5). This construct was
engineered to substitute the basic amino acids of the two cleavage
sites by asparagines, as done for FcN and FcN2C-C (see previous
section). Four milligrams of purified FTM- were covalently linked
to CNBr-activated Sepharose beads to make FTM-Sepharose
columns, following manufacturer’s recommendations.
FcN and FcN2C-C proteins were solubilized from CV-1 cells
infected with the respective recombinant vaccinia viruses in
a buffer containing: 50 mM sodium phosphate at pH 8.0, 300 mM
NaCl, 10 mM imidazole, and 1% octyl-glucoside. The solubilized
proteins were loaded onto columns of His-Select Nickel affinity
gel (Sigma) and washed with the same buffer containing 20 mM
imidazole. The proteins retained in the columns were eluted by
increasing the imidazole concentration to 250 mM. Protein purity
was confirmed by SDS/PAGE and Western blot analysis.
Rabbit Immunization, Purification of Antibodies and Depletion of
Conformation Specific Antibodies. New Zealand White rabbits
were inoculated intramuscularly (i.m.) on days 0 and 21 with 107
pfu of vaccinia recombinants encoding the proteins mentioned in
each case. Groups of two or three rabbits were inoculated with
each virus. Sera were collected 3 wk later and pooled by group.
Total antibodies were purified by using protein A-Sepharose
columns as recommended by the manufacturer (GE Healthcare).
Depletion of α-FTM- antibodies was achieved by loading purified
total antibodies onto a FTM- Sepharose column. The unretained
material containing the depleted antibodies was collected and
saved, and the antibodies bound to the column were eluted with
0.1 M Glycine-HCl at pH 2.5 and neutralized with saturated Tris.
Depletion of specific antibodies was also achieved by incubating
100–300 μg of total antibodies for 30 min at room temperature
with 107 HEp-2 cells infected 24 h earlier with recombinant
vaccinia viruses at a multiplicity of 5 infectious units per cell.
After incubation, cells were pelleted by centrifugation at low
speed and the supernatants were collected and saved until used.
Depletion of antibodies present in a human Ig preparation
(Respigam) was done as for the rabbit antibodies.
Antibodies specific for the six-helix bundle (6HB) of the post-
fusion F protein were generated by inoculation of rabbits with 100
μg of a protein made of GST followed by HRA (aa 160–207) and
HRB (aa 479–520) linked by the sequence GSSGG. The protein
was purified by standard procedures using glutathione-Sepharose
and mixed with an equal volume of Freund’s adjuvant for in-
oculation into rabbits. Animals were bled 3 wk after injection.
Nomenclature of Polyclonal Antibodies. The rabbit antibodies used
in this study have been named according to the following system:
The first part of the name refers to the protein encoded by the
vaccinia recombinant used in the immunization, followed by the
manipulations made in vitro, indicated in boldface. For instance,
α-Fc/ΔFTM- correspond to antibodies raised in rabbits inoculated
with Vac/Fc and that were depleted of those binding to FTM-.
This system has also been used to label the antibodies derived
from the Respigam (RG) preparation.
Immunoassays. ELISAs were performed in 96-well plates coated
with purified recombinant proteins, FTM-, FcN, and FcN2C-C
either by direct adsorption to the plastic or by capture with
a specific monoclonal antibody MAb 101F. Nonspecific antibody
binding was blocked with 2% porcine serum in PBS with 0.05%
Tween 20. Antibody preparations were incubated on plates for
1 h at 37 °C, and unbound antibody was removed by washing five
times with water. Antibody binding was assessed by incubation
with a peroxidase-conjugated anti-rabbit or anti-human second-
ary antibody (GE Healthcare) and subsequent addition of OPD
(Sigma) as substrate.
Western blotting was done after separation of proteins by SDS/
PAGE and electrotransfer to nylon membranes that were de-
veloped with the antibodies indicated in the figure legends and
Lumigen assays (GE Healthcare).
Microneutralization tests were performed in 96-well plates with
90% confluent HEp-2 cell monolayers (6). The Long strain of
hRSV was used to infect the monolayers (0.2–0.5 infectious units
per cell) either in the presence or absence of antibodies.After 72 h,
themediumwas removed, and after washingwith 0.05%Tween-20
in PBS, cells were fixedwith chilled 80%acetone in PBS. Then, the
amount of viral antigen in each well was quantified by ELISA,
using a pool of MAbs specific for the F and G glycoproteins (6).
Neutralization is referred as reduction of viral antigen production
normalized to an infected control without antibody.
Cytometry of cells infected with hRSV and recombinant
vaccinia viruses was performed by standard procedures, after
detaching the cells from the plates with 10 mM EDTA in PBS.
Electron Microscopy. Two to five microliters of each purified
protein was applied to glow-discharged carbon-coated grids and
negatively stained with 2% aqueous uranyl acetate. Micrographs
were recorded with a Tecnai 12 FEI microscope operated at 120
kV at a nominal magnification of 67,000×.
1. Llorente MT, et al. (2008) Structural properties of the human respiratory syncytial virus
P protein: Evidence for an elongated homotetrameric molecule that is the smallest
orthologue within the family of paramyxovirus polymerase cofactors. Proteins 72:
946–958.
2. Bembridge GP, Garcia-Beato R, López JA, Melero JA, Taylor G (1998) Subcellular site of
expression and route of vaccination influence pulmonary eosinophilia following
respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G
protein. J Immunol 161:2473–2480.
3. Bembridge GP, et al. (1999) Priming with a secreted form of the fusion protein of
respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 produc-
tion but not pulmonary eosinophilia following RSV challenge. J Virol 73:10086–
10094.
Magro et al. www.pnas.org/cgi/content/short/1115941109 1 of 3
4. Blasco R, Moss B (1995) Selection of recombinant vaccinia viruses on the basis of plaque
formation. Gene 158:157–162.
5. Calder LJ, et al. (2000) Electronmicroscopy of the human respiratory syncytial virus fusion
protein and complexes that it forms with monoclonal antibodies. Virology 271:122–131.
6. Magro M, Andreu D, Gómez-Puertas P, Melero JA, Palomo C (2010) Neutralization
of human respiratory syncytial virus infectivity by antibodies and low-molecular-
weight compounds targeted against the fusion glycoprotein. J Virol 84:7970–
7982.
Fig. S1. Virus neutralization by antibodies after ultracentrifugation. The Long strain of hRSV [8 × 105 infectious units (pfu)] were incubated with 10-fold excess
of the minimal neutralizing dose of α-Fc, α-Fc/ΔFTM-, and α-Fc/FTM- antibodies (previously titrated; pre is the same amount as α-Fc but of preimmune antibody)
for 30 min at 37 °C. Then, samples were loaded on top of a 25% glycerol cushion in PBS and ultracentrifuged at 126,000 × g for 2 h. Pellets were resuspended in
DMEM2.5 and used to infect HEp-2 cells. Viral antigen produced after 72 h was quantified by ELISA as indicated in Methods. Results are representative of two
independent experiments.
Fig. S2. The neutralizing activity of rabbit α-Fc/ΔFTM- antibodies is ablated by depletion with either Vac/Fc or Vac/FcN2C-C infected cells. The purified α-Fc
antibodies (raised in rabbits inoculated with Vac/Fc) that did not bind to the column of FTM-Sepharose (α-Fc/ΔFTM-) were incubated with HEp-2 cells infected
with Vac/P (α-Fc/ΔFTM-/ΔVac), Vac/Fc (α-Fc/ΔFTM-/ΔFc), or Vac/FcN2C-C (α-Fc/ΔFTM-/ΔFcN2C-C). After adsorption, the antibodies were used in a microneutralization
test with hRSV. Note that incubation of antibodies with cells infected with Vac/P had no effect on neutralization but incubation with cells infected with either
Vac/Fc or Vac/ FcN2C-C ablated the neutralizing activity of α-Fc/ΔFTM- antibodies. C- is a preimmune rabbit antibody. Results are presented as means ± SEM of
three independent experiments.
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Fig. S3. Immunogenitiy of Vac/FcN2C-C. New Zealand White rabbits were inoculated with Vac/FcN2C-C. The antiserum (named α-FcN2C-C) was tested for binding
to FTM- adsorbed to ELISA plates (Left) or hRSV neutralization (Right). The antiserum raised against Vac/Fc (α-Fc) or preimmune serum were tested in parallel.
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